Known genetic risk factors for venous thrombosis, such as Factor V Leiden and prothrombin, only partially account for the genetic contribution to deep vein thrombosis (DVT). In collaboration with scientists at the University of Leiden Medical Center, Celera has discovered several new associations with variants in other genes in the coagulation pathway. These discoveries have potential for improving the prediction of risk of DVT, pulmonary embolism, adverse pregnancy outcomes, recurrent DVT, cancer-related DVT, and for pharmacogenomic studies on the efficacy of new drugs for prevention of thrombosis.